Raul Morales Borges, MD
Hematology & Oncology · San Juan, PRNPI 1063412047
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,611 of the $7,554 with a category attached, or 74.3%. 23 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 34.7% of the total. That places this record below the midpoint for hematology & oncology clinicians in PR, where the typical reported total is $10,882.
Across 240 payments — averaging $31.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$3K
- Johnson & Johnson$985
- Janssen Scientific Affairs, LLC$975
- Eli Lilly Export S.A. Puerto Rico Branch$678
- AstraZeneca$566
- Merck$474
- plus $1K from 17 others
Across 2 payments — averaging $21,462 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Immunomedics, Inc.$38K
- Gilead$5K
What the payments were for
- Consulting fees$97513%
- Food & beverage$5,61174%
- Education$96813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 119 | $2,622 |
| Johnson & Johnson(2 entities) | 19 | $985 |
| Janssen Scientific Affairs, LLC | 1 | $975 |
| Eli Lilly Export S.A. Puerto Rico Branch | 26 | $678 |
| AstraZeneca | 20 | $566 |
| Merck | 6 | $474 |
| AbbVie | 12 | $277 |
| Rigel Pharmaceuticals, Inc. | 2 | $140 |
| Pfizer | 4 | $139 |
| Pharmaessentia USA Corporation | 5 | $128 |
| PBG Puerto Rico LLC | 5 | $107 |
| Incyte Corporation | 4 | $76 |
| Sobi, Inc | 3 | $67 |
| Boehringer Ingelheim | 1 | $66 |
| Sanofi | 3 | $55 |
| Novartis | 2 | $44 |
| Karyopharm Therapeutics Inc. | 2 | $43 |
| Amgen | 1 | $29 |
| Bristol Myers Squibb | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Eisai Inc. | 1 | $13 |
| Array Biopharma Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,554 in reported general payments places this provider in the 40th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 53 | $788,353 |
| PromactaEltrombopag Olamine | 68 | $770,780 |
| IbrancePalbociclib | 41 | $647,003 |
| RevlimidLenalidomide | 26 | $465,307 |
| JakafiRuxolitinib Phosphate | 26 | $447,750 |
| CalquenceAcalabrutinib Maleate | 24 | $372,911 |
| XtandiEnzalutamide | 26 | $370,269 |
| XalkoriCrizotinib | 12 | $272,099 |
| XgevaDenosumab | 12 | $37,800 |
| EliquisApixaban | 35 | $23,299 |
| RetacritEpoetin Alfa-Epbx | 22 | $17,831 |
| Anastrozole | 206 | $3,000 |
| SynthroidLevothyroxine Sodium | 38 | $2,400 |
| Tranexamic Acid | 23 | $2,326 |
| Sulindac | 65 | $1,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Xalkori, Eliquis, Retacrit | $139 | $960,232110 claims |
| Johnson & JohnsonErleada | $985 | $788,35353 claims |
| NovartisPromacta | $44 | $770,78068 claims |
| Bristol Myers SquibbRevlimid | $23 | $465,30726 claims |
| Incyte CorporationJakafi | $76 | $447,75026 claims |
| AstraZenecaCalquence | $566 | $372,91124 claims |
| AmgenXgeva | $29 | $37,80012 claims |
| AbbVieSynthroid | $277 | $2,40038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in San Juan
- Alexis Cruz ChaconSan Juan$450K
- Jose Lozada CostasSan Juan$260K
- Cristian Rodriguez ArochoSan Juan$227K
- Noridza Rivera RodriguezSan Juan$177K
- Mirelis AcostaSan Juan$154K
- Luis Baez VallecilloSan Juan$107K
- Edgardo Santiago-GuzmanSan Juan$79K
- Adelba Torres-LopezSan Juan$73K
- Karla Feliciano SalvaSan Juan$44K
- Luis Delgado MateuSan Juan$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.